Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine
ConditionPostoperative Pain Management
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorRhode Island Hospital
About this trial
The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.
Eligibility criteria
Qualifiers
Patients undergoing elective total hip arthroplasty
18-80 years old
ASA 1-3 classifications
Disqualifiers
ASA classification of 4 or greater
Infection at the site of nerve blockade
Coagulopathy
Known allergy to study medications
Trial design
Treatments tested in this trial
- Dexmedetomidine
- Ropivacaine
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov